Edit |   |
---|---|
Antigenic Specificity | CTLA4/CD152 (Tremelimumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG2 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Tremelimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CTLA4/CD152, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. |
Immunogen | n/a |
Other Names | Tremelimumab, CTLA4/CD152, 745013-59-6 |
Gene, Accession # | CAS: 745013-59-6 |
Catalog # | abx831132 |
Price | please inquire |
Order / More Info | CTLA4/CD152 (Tremelimumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950